On the stock market since 2016, it operates in the world of health and science. It has 91 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 36% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $5.0B against $1.4B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.56. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, SYMQY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SYMQY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.